Video: Closed System CGT Manufacturing: The Future of Scale-up and Commercialization
Video Summary
Join us for an interview from Phacilitate‘s Advanced Therapies Week 2025 with two industry experts from Bio-Techne as they explore the critical challenges and opportunities in closed system manufacturing for cell and gene therapies (CGTs). Our experts examine how innovative manufacturing approaches—particularly closed systems and automation—can help bridge the gap between promising therapies and successful market deployment.
The conversation will delve into practical strategies for balancing flexibility and standardization in process development, addressing raw material challenges, and implementing automation effectively. They will also share their vision for the technological advances needed to transform CGT manufacturing over the next 3-5 years, offering valuable insights for organizations looking to future-proof their CGT programs.
This interview features David Hermanson, Ph.D., Principal Scientist, Cell and Gene Therapy Applications and Steven Dublin, Senior Manager, Cell and Gene Therapy - EMEA, in January 2025.
Learn more about Bio-Techne's closed process solution for T cell manufacturing.